AI Article Synopsis
- - Recent trials show that prophylactic vaccines can effectively stimulate CD8+ T-cell responses, helping to control infections from a pathogenic simian-human immunodeficiency virus (SHIV) in macaques.
- - In the chronic phase of infection, boosting virus-specific CD8+ T-cells through therapeutic immunization may enhance the control of virus replication.
- - This study demonstrates that administering a recombinant Sendai virus (SeV) vector to vaccinated macaques can successfully expand and broaden the CD8+ T-cell responses in those who have already controlled SHIV for over a year.
Article Abstract
Recent prophylactic vaccine trials inducing virus-specific CD8+ T-cell responses have shown control of primary infections of a pathogenic simian-human immunodeficiency virus (SHIV) in macaques. In the chronic phase, therapeutic immunization replenishing virus-specific CD8+ T-cells is likely to contribute to sustained control of virus replication. In this study, we have administered a recombinant Sendai virus (SeV) vector into five rhesus macaques that had received prophylactic vaccinations and had controlled SHIV replication for more than 1 year after challenge. Our results indicate that virus-specific CD8+ T-cell responses can be expanded and broadened by therapeutic immunization with SeV vectors in the chronic phase after prophylactic vaccine-based control of primary immunodeficiency virus infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2004.12.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!